# Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

> **NCT01593696** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 53 (actual)

## Conditions studied

- ALL
- B Cell Lymphoma
- Leukemia
- Large Cell Lymphoma
- Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)

## Key facts

- **NCT ID:** NCT01593696
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-29
- **Primary completion:** 2016-11-11
- **Final completion:** 2017-10-02
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593696, "Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01593696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*